Andre Franke, PhD


Andre Franke (*1978) is the director of the Institute of Clinical Molecular Biology (IKMB) and leads the high-throughput laboratory facilities (biobank, sequencing and genotyping, microbiome labs) as well as the bioinformatics unit of the Centre for Molecular Life Sciences (ZMB) at Kiel University. He studied biology and informatics from 1998-2003 and received his PhD degree in 2006 from the Christian-Albrechts-University of Kiel (CAU) in Northern Germany. In his PhD thesis he disovered for the first time that autophagy is an important pathway in IBD etiology (Hampe & Franke et al., Nat Genet 2007). With 29 years of age and until 2011 he became assistant (W1) professor for “Epithelial Barrier Diseases” at Kiel University. In 2011 he received an (W2, associate) Endowment Professorship of the Foundation of Experimental Biomedicine (Zürich, Switzerland) and in 2016 he became a (W3) full professor for “Molecular Medicine” at Kiel University. In 2008 he received the Hensel Prize for excellent research (100,000 €), in 2012 the Ludwig-Demling Research Prize of the German Crohn’s and Colitis Foundation (DCCV) and in 2017 the Thannhauser Prize of the DGVS (German Society for Gastroenterology; 10,000 €). Franke has a strong theoretical and methodological background in human genetics and bioinformatics. The main focus of his research group is on complex, chronic inflammatory diseases such as inflammatory bowel diseases (IBD), psoriasis or primary sclerosing cholangitis and technology development, to which he made several important scientific contributions.


Since 2012, Franke is spokesperson of the PhD training program “Genes, Environment, and Inflammation” (DFG Research Training Group 1743) and since 2020 spokesperson of the DFG Research Unit miTarget. He co-authors over 533 research articles with a cumulative impact factor of >5,981 (h-index of 94 according to Scopus).